tarenflurbil has been researched along with sulindac sulfide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bain, G; Beher, D; Chen, W; Jiang, X; Munoz, B; Peachey, J; Prasit, P; Shearman, MS; St-Jacques, R; Stock, N; Williamson, TL; Wrigley, JD | 1 |
| Baumann, K; Dittrich, M; Greiner, C; Hieke, M; Ness, J; Schubert-Zsilavecz, M; Steri, R; Weggen, S; Werz, O; Zettl, H | 1 |
| Berthelot, DJ; Gijsen, HJ; Oehlrich, D | 1 |
1 review(s) available for tarenflurbil and sulindac sulfide
| Article | Year |
|---|---|
γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cinnamates; Clinical Trials as Topic; Ginsenosides; Humans; Isoenzymes; Stereoisomerism | 2011 |
2 other study(ies) available for tarenflurbil and sulindac sulfide
| Article | Year |
|---|---|
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Flurbiprofen; Mice; Peptide Fragments | 2006 |
Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Caproates; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Cyclooxygenase Inhibitors; Drug Design; Humans; Peptide Fragments; PPAR gamma; Pyrimidines; Receptors, Notch; Sheep; Structure-Activity Relationship; Transcriptional Activation | 2010 |